Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.
Agnès
A
Lillo-Le Louët
Martine
M
Wolf
Lilia
L
Soufir
Arnaud
A
Galbois
Anne-Sylvie
AS
Dumenil
Georges
G
Offenstadt
Meyer-Michel
MM
Samama
D000368:Aged; D000369:Aged, 80 and over; D000991:Antithrombins / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019643:Arthroplasty, Replacement; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D003082:Colectomy; D003131:Combined Modality Therapy; D000069604:Dabigatran; D004630:Emergencies; D017707:Erythrocyte Transfusion; D015942:Factor VIIa / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000378:metabolism; D008297:Male; D010949:Plasma; D019106:Postoperative Hemorrhage / Q000139:chemically induced* / Q000601:surgery / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D012151:Resuscitation / Q000379:methods*; D019851:Thrombophilia / Q000188:drug therapy; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000991:Antithrombins; D001562:Benzimidazoles; D001779:Blood Coagulation Factors; D006490:Hemostatics; D011994:Recombinant Proteins; D015091:beta-Alanine; C025667:prothrombin complex concentrates; C103587:recombinant FVIIa; D015942:Factor VIIa; D000069604:Dabigatran